{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:05:01Z","timestamp":1790208301229,"version":"4.1.0"},"reference-count":386,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015999","name":"Lucian Blaga University of Sibiu","doi-asserted-by":"publisher","award":["LBUS-IRG-2024\/No. 6112"],"award-info":[{"award-number":["LBUS-IRG-2024\/No. 6112"]}],"id":[{"id":"10.13039\/501100015999","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Coagulation is a physiological process necessary to achieve homeostasis. Many pathologies lead to spontaneous activation of the coagulation pathways and increase the risk of venous thrombosis (e.g., atrial fibrillation, orthopaedic surgery, cancer). Therefore, a lot of patients need anticoagulant drugs as preventive or curative treatment. In general, older molecules (unfractionated heparin, low-molecular-weight heparins, vitamin K antagonists) have good efficacy. Still, their adverse reactions, increased risk of bleeding, or difficult administration led to low adherence to treatment and had even limited their use. Recently, new molecules were authorised to improve patient adherence to treatment, mainly formulated for oral administration (e.g., dabigatran, rivaroxaban, apixaban, etc.). This therapeutic approach has a low risk of bleeding and does not require special monitoring by laboratory tests. Also, new anticoagulants for patients with heparin-induced thrombocytopenia (e.g., argatroban, lepirudin, bivalirudin, etc.) were obtained. Moreover, reversal agents for the new anticoagulant molecules used in overdoses or in situations where immediate cessation of the anticoagulant effect is required (e.g., emergency surgery) were studied, some of them being authorised on the pharmaceutical market. This narrative review aims to provide a pharmacological and therapeutic overview of anticoagulant drugs, underlining their implementation and limitations.<\/jats:p>","DOI":"10.3390\/pharmaceutics18020163","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T15:48:30Z","timestamp":1769442510000},"page":"163","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["An Overview of Anticoagulant Drugs Pharmacology, Therapeutic Approaches, Limitations and Perspectives"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2730-8729","authenticated-orcid":false,"given":"Claudiu","family":"Morgovan","sequence":"first","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4874-0430","authenticated-orcid":false,"given":"Adina","family":"Frum","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7451-1901","authenticated-orcid":false,"given":"Laurentiu","family":"Stoicescu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Vth Medical Clinic, Faculty of Medicine, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy, 400139 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1540-641X","authenticated-orcid":false,"given":"Anca","family":"Butuca","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9913-1750","authenticated-orcid":false,"given":"Carmen Maximiliana","family":"Dobrea","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9801-0060","authenticated-orcid":false,"given":"Anca Maria","family":"Arseniu","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3128-2763","authenticated-orcid":false,"given":"Adriana Aurelia","family":"Chis","sequence":"additional","affiliation":[{"name":"Association for Excellence in Pharmaceutical Education and Research, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7723-8418","authenticated-orcid":false,"given":"Maria Lucia","family":"Muresan","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3167-9864","authenticated-orcid":false,"given":"Felicia Gabriela","family":"Gligor","sequence":"additional","affiliation":[{"name":"Preclinical Department, Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5281-5004","authenticated-orcid":false,"given":"Ioana Rada","family":"Popa Ilie","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Faculty of Medicine, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy, 3-5 Louis Pasteur Street, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2247-4613","authenticated-orcid":false,"given":"Steliana","family":"Ghibu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Physiology and Pathophysiology, Faculty of Pharmacy, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy, 6A Louis Pasteur Street, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"ref_1","unstructured":"Liebson, P.R. (2013). The Early History of Anticoagulants: 1915\u20131948. Hektoen Int. J. Med. Humanit., 5."},{"key":"ref_2","unstructured":"(2022, May 09). Milestones in Anticoagulant Drugs. Available online: https:\/\/www.hematology.org\/about\/history\/50-years\/milestones-anticoagulant-drugs."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000216256","article-title":"The History of Leeching and Hirudin","volume":"21","author":"Fields","year":"1991","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3923\/pjbs.2008.1650.1653","article-title":"Leeching in the History\u2014A Review","volume":"11","author":"Munshi","year":"2008","journal-title":"Pak. J. Biol. Sci."},{"key":"ref_5","unstructured":"Hsu, E., and Moosavi, L. (2021). Biochemistry, Antithrombin III, StatPearls."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/bcp.14081","article-title":"Biosimilars of Low Molecular Weight Heparins: Relevant Background Information for Your Drug Formulary","volume":"85","author":"Brouwers","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_7","unstructured":"(2022, June 29). Clivarin\u2014Summary of the Product Characteristics. Available online: https:\/\/www.e-lactancia.org\/media\/papers\/ReviparinClivarin-DS-SmPC2010.pdf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12959-017-0136-2","article-title":"The Introduction of Biosimilars of Low Molecular Weight Heparins in Europe: A Critical Review and Reappraisal Endorsed by the Italian Society for Haemostasis and Thrombosis (SISET) and the Italian Society for Angiology and Vascular Medicine (SIAPAV)","volume":"15","author":"Imberti","year":"2017","journal-title":"Thromb. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ihj.2012.12.024","article-title":"Drug Lag for Cardiovascular Drug Approvals in India Compared with the US and EU Approvals","volume":"65","author":"Kataria","year":"2013","journal-title":"Indian Heart J."},{"key":"ref_10","unstructured":"Troein, P., Newton, M., and Scott, K. (2022, June 29). The Impact of Biosimilar Competition in Europe. Available online: https:\/\/health.ec.europa.eu\/system\/files\/2021-01\/biosimilar_competition_en_0.pdf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1160\/TH07-10-0644","article-title":"Bivalirudin","volume":"99","author":"Warkentin","year":"2008","journal-title":"Thromb. Haemost."},{"key":"ref_12","unstructured":"(2022, June 29). Enoxaparin\u2014StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK539865\/."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.21037\/jtd.2018.03.95","article-title":"Recent Progress and Market Analysis of Anticoagulant Drugs","volume":"10","author":"Fan","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2217\/fca-2019-0038","article-title":"Andexanet Alfa for Reversal of Factor Xa Inhibitors: A Critical Review of the Evidence","volume":"15","author":"Abdulrehman","year":"2019","journal-title":"Future Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s40265-015-0508-5","article-title":"Idarucizumab: First Global Approval","volume":"75","author":"Burness","year":"2015","journal-title":"Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2174\/1389200218666170417124035","article-title":"Laboratory Monitoring or Measurement of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges","volume":"18","author":"Favaloro","year":"2017","journal-title":"Curr. Drug Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0300-9084(03)00078-6","article-title":"1976\u20131983, a Critical Period in the History of Heparin: The Discovery of the Antithrombin Binding Site","volume":"85","author":"Petitou","year":"2003","journal-title":"Biochimie"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"106918","DOI":"10.1016\/j.vph.2021.106918","article-title":"Eighty Years of Oral Anticoagulation: Learning from History","volume":"141","author":"Montinari","year":"2021","journal-title":"Vasc. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nrd.2018.89","article-title":"The Market for Oral Anticoagulants","volume":"17","author":"Bielecki","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.2741\/4462","article-title":"Heparin and Anticoagulation","volume":"21","author":"Onishi","year":"2016","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"ref_21","unstructured":"(2022, June 13). Global Anticoagulants Market (2021\u20132026) by Drug Class, Route of Administration, Geography and the Impact of COVID-19 with Ansoff Analysis. Available online: https:\/\/www.researchandmarkets.com\/reports\/5317270\/global-anticoagulants-market-2021-2026-by-drug."},{"key":"ref_22","unstructured":"(2022, May 09). Anticoagulant Reversal Drugs Market Size Report, 2020\u20132027. Available online: https:\/\/www.grandviewresearch.com\/industry-analysis\/anticoagulant-reversal-drugs-market."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/B978-0-12-394447-4.10079-3","article-title":"Overview of Blood Coagulation and the Pathophysiology of Blood Coagulation Disorders","volume":"Volume 1","author":"Cardenas","year":"2016","journal-title":"Encyclopedia of Cell Biology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1152\/physrev.00016.2011","article-title":"New Fundamentals in Hemostasis","volume":"93","author":"Versteeg","year":"2013","journal-title":"Physiol. Rev."},{"key":"ref_25","unstructured":"Ashorobi, D., Ameer, M.A., and Fernandez, R. (2022, June 29). Thrombosis. StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538430\/."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"264","DOI":"10.5811\/westjem.2016.3.29294","article-title":"Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016","volume":"17","author":"Christos","year":"2016","journal-title":"West. J. Emerg. Med."},{"key":"ref_27","first-page":"115","article-title":"Anticoagulants","volume":"Volume 4","author":"Ruppert","year":"2006","journal-title":"Encyclopedia of Respiratory Medicine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2174\/0929867053363108","article-title":"Modulators of the Coagulation Cascade: Focus and Recent Advances in Inhibitors of Tissue Factor, Factor VIIa and Their Complex","volume":"12","author":"Frederick","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s11239-021-02455-x","article-title":"Factor Xa Inhibitors: Critical Considerations for Clinical Development and Testing","volume":"52","author":"Becker","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Munlemvo, D.M. (2025). The Cell-Based Approach of Hemostasis, Coagulopathy, and the Implications for the Pediatric Cardiac Anesthesiologist. Front. Anesthesiol., 4.","DOI":"10.3389\/fanes.2025.1454904"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1172\/JCI60229","article-title":"New Insights into the Mechanisms of Venous Thrombosis","volume":"122","author":"Mackman","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.4155\/fmc-2015-0020","article-title":"Structure\u2013Activity Relationship Studies for Multitarget Antithrombotic Drugs","volume":"8","author":"Neves","year":"2016","journal-title":"Future Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/applnano2020009","article-title":"Applied Nanotechnologies in Anticoagulant Therapy: From Anticoagulants to Coagulation Test Performance of Drug Delivery Systems","volume":"2","author":"Patriota","year":"2021","journal-title":"Appl. Nano"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000069103","article-title":"An Overview of the Direct Thrombin Inhibitor Argatroban","volume":"32","author":"Walenga","year":"2002","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/14656566.1.4.803","article-title":"Danaparoid Sodium","volume":"1","author":"Acostamadiedo","year":"2005","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/00003495-199754060-00008","article-title":"Danaparoid. A Review of Its Pharmacology and Clinical Use in the Management of Heparin-Induced Thrombocytopenia","volume":"54","author":"Wilde","year":"1997","journal-title":"Drugs"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1160\/TH08-01-0032","article-title":"Heparin and Low-Molecular-Weight Heparin","volume":"99","author":"Gray","year":"2008","journal-title":"Thromb. Haemost."},{"key":"ref_39","unstructured":"(2022, June 29). Anticoagulation Products (LMWHs, Ultra LMWH, Direct Thrombin Inhibitors). Available online: https:\/\/hemonc.medicine.ufl.edu\/files\/2013\/07\/AnticoagRx.pdf."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Thomas, O., Lybeck, E., Strandberg, K., Tynng\u00e5d, N., and Sch\u00f6tt, U. (2015). Monitoring Low Molecular Weight Heparins at Therapeutic Levels: Dose-Responses of, and Correlations and Differences between APTT, Anti-Factor Xa and Thrombin Generation Assays. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0116835"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3109\/10409238.2015.1050550","article-title":"How It All Starts: Initiation of the Clotting Cascade","volume":"50","author":"Smith","year":"2015","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.nec.2018.06.003","article-title":"Anticoagulants: Pharmacokinetics, Mechanisms of Action, and Indications","volume":"29","author":"DeWald","year":"2018","journal-title":"Neurosurg. Clin. N. Am."},{"key":"ref_43","unstructured":"(2022, June 30). HEPARIN Injectable|MSF Medical Guidelines. Available online: https:\/\/medicalguidelines.msf.org\/en\/viewport\/EssDr\/english\/heparin-injectable-16682769.html."},{"key":"ref_44","unstructured":"(2022, June 30). Heparin Infusion Guidelines|Anticoagulation Services. Available online: https:\/\/depts.washington.edu\/anticoag\/home\/content\/heparin-infusion-guidelines."},{"key":"ref_45","unstructured":"(2022, June 30). Guidelines for Heparin Dosage\u2014Manchester University NHS Foundation Trust. Available online: https:\/\/mft.nhs.uk\/the-trust\/other-departments\/laboratory-medicine\/haematology\/reference-ranges\/#heparin."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1111\/bcp.13340","article-title":"Initial Anticoagulation in Patients with Pulmonary Embolism: Thrombolysis, Unfractionated Heparin, LMWH, Fondaparinux, or DOACs?","volume":"83","author":"Leentjens","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1517\/17425247.2016.1125880","article-title":"Recent Advances in Anticoagulant Drug Delivery","volume":"13","author":"Park","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_48","unstructured":"(2022, June 30). Fragmin\u2014Summary of Product Characteristics. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/4241\/smpc\/print."},{"key":"ref_49","unstructured":"(2022, June 30). Fraxiparine\u2014Summary of Product Characteristics. Available online: https:\/\/www.anm.ro\/_\/_RCP\/rcp_2518_10.05.10.pdf."},{"key":"ref_50","unstructured":"(2022, June 30). CHMP Lovenox\u2014Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/lovenox-article-30-referral-annex-iii_en.pdf."},{"key":"ref_51","unstructured":"(2022, June 30). INNOHEP\u2014R\u00e9sum\u00e9 Des Caract\u00e9ristiques Du Produit. Available online: http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0287004.htm."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"132S","DOI":"10.1378\/chest.119.1_suppl.132S","article-title":"Prevention of Venous Thromboembolism","volume":"119","author":"Geerts","year":"2001","journal-title":"Chest"},{"key":"ref_53","unstructured":"(2022, June 30). DVT and Pulmonary Embolism: Part II. Treatment and Prevention, American Family Physician, Available online: https:\/\/www.aafp.org\/pubs\/afp\/issues\/2004\/0615\/p2841.html."},{"key":"ref_54","unstructured":"(2022, June 30). CHMP Arixtra\u2014Annex I Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/arixtra-epar-product-information_en.pdf."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2165\/00003088-200544120-00003","article-title":"Comparative Pharmacokinetics of Vitamin K Antagonists: Warfarin, Phenprocoumon and Acenocoumarol","volume":"44","author":"Ufer","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-2007-996417","article-title":"Pharmacokinetic and Pharmacodynamic Properties of Oral Anticoagulants, Especially Phenprocoumon","volume":"25","author":"Haustein","year":"1999","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11239-016-1446-0","article-title":"Vitamin K Antagonists: Relative Strengths and Weaknesses vs. Direct Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation","volume":"43","author":"Zirlik","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Saha, N. (2018). Clinical Pharmacokinetics and Drug Interactions. Pharmaceutical Medicine and Translational Clinical Research, Academic Press.","DOI":"10.1016\/B978-0-12-802103-3.00006-7"},{"key":"ref_59","unstructured":"(2022, June 30). CHMP Xarelto\u2014Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xarelto-epar-product-information_en.pdf."},{"key":"ref_60","unstructured":"(2022, June 30). CHMP Eliquis\u2014Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eliquis-epar-product-information_en.pdf."},{"key":"ref_61","unstructured":"(2025, March 30). Zibor\u2014Summary of Product Characteristics. Available online: https:\/\/assets.hpra.ie\/products\/Human\/27479\/Licence_PA25279-001-001_10012025162847.pdf."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2013.06.007","article-title":"Evolution of Heparin Anticoagulants to Ultra-Low-Molecular-Weight Heparins: A Review of Pharmacologic and Clinical Differences and Applications in Patients with Cancer","volume":"88","author":"Walenga","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_63","unstructured":"(2022, June 30). Danaparoid Sodium 750 Anti-Xa Units\/0.6 Ml, Solution for Injection\u2014Summary of Product Characteristics (SmPC)\u2013(Emc). Available online: https:\/\/www.medicines.org.uk\/emc\/product\/13201\/smpc#gref."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.2165\/00003495-200262150-00016","article-title":"Danaparoid: A Review of Its Use in Thromboembolic and Coagulation Disorders","volume":"62","author":"Ibbotson","year":"2002","journal-title":"Drugs"},{"key":"ref_65","unstructured":"(2022, June 30). CHMP Elmiron\u2014Annex I Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elmiron-epar-product-information_en.pdf."},{"key":"ref_66","unstructured":"(2022, June 30). FDA Argatroban\u2014Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212035s000lbl.pdf."},{"key":"ref_67","unstructured":"(2022, June 30). FDA Iprivask\u2014Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021271s006lbl.pdf."},{"key":"ref_68","unstructured":"(2022, June 30). CHMP Refludan\u2014Annex I Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/refludan-epar-product-information_en.pdf."},{"key":"ref_69","unstructured":"(2022, June 30). CHMP Angiox\u2014Annex I Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/angiox-epar-product-information_en.pdf."},{"key":"ref_70","unstructured":"(2022, June 30). Pradaxa\u2014Summary of Product Characteristics I. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pradaxa-epar-product-information_en.pdf."},{"key":"ref_71","unstructured":"(2022, June 30). CHMP Roteas\u2014Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/roteas-epar-product-information_en.pdf."},{"key":"ref_72","unstructured":"(2022, June 30). FDA Bevyxxa\u2014Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208383s000lbl.Pdf."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"van Miert, J.H.A., Veeger, N.J.G.M., Ten Cate-Hoek, A.J., Piersma-Wichers, M., and Meijer, K. (2020). Effect of Switching from Acenocoumarol to Phenprocoumon on Time in Therapeutic Range and INR Variability: A Cohort Study. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0235639"},{"key":"ref_75","first-page":"679","article-title":"Meenu Acenocoumarol\u2019s Pharmacokinetic: Linear or Not?","volume":"18","author":"Kumar","year":"2019","journal-title":"EXCLI J."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Ferri, N., Colombo, E., Tenconi, M., Baldessin, L., and Corsini, A. (2022). Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061120"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40138-013-0014-6","article-title":"Anticoagulants: A Review of the Pharmacology, Dosing, and Complications","volume":"1","author":"Alquwaizani","year":"2013","journal-title":"Curr. Emerg. Hosp. Med. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0167-5273(16)12001-7","article-title":"Heparin Centenary\u2014An Ever-Young Life-Saving Drug","volume":"212","author":"Torri","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.drudis.2014.07.004","article-title":"Structural and Functional Analyses of Bovine and Porcine Intestinal Heparins Confirm They Are Different Drugs","volume":"19","author":"Santos","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.2174\/092986709788803105","article-title":"Structure-Activity Relationships of Low Molecular Weight Heparins Expose to the Risk of Achieving Inappropriate Targets in Patients with Renal Failure","volume":"16","author":"Stratta","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low-Molecular-Weight Heparins","volume":"337","author":"Weitz","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00003088-200241002-00002","article-title":"Fondaparinux Sodium Mechanism of Action: Identification of Specific Binding to Purified and Human Plasma-Derived Proteins","volume":"41","author":"Paolucci","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000216930","article-title":"Interactions of Heparins in the Vascular Environment","volume":"23","author":"Dawes","year":"1993","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S0167-5273(16)12004-2","article-title":"Old and New Applications of Non-Anticoagulant Heparin","volume":"212","author":"Cassinelli","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"McRae, H.L., Militello, L., and Refaai, M.A. (2021). Updates in Anticoagulation Therapy Monitoring. Biomedicines, 9.","DOI":"10.3390\/biomedicines9030262"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"26","DOI":"10.21037\/aob.2019.11.01","article-title":"Anticoagulation Therapy in Iran","volume":"4","author":"Dorgalaleh","year":"2019","journal-title":"Ann. Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5543460","DOI":"10.1155\/2021\/5543460","article-title":"Techniques for Detection of Clinical Used Heparins","volume":"2021","author":"Li","year":"2021","journal-title":"Int. J. Anal. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e495S","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Linkins","year":"2012","journal-title":"Chest"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"281","DOI":"10.31083\/j.rcm2508281","article-title":"Current Antithrombotic Treatments for Cardiovascular Diseases: A Comprehensive Review","volume":"25","author":"Galanti","year":"2024","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_90","first-page":"224","article-title":"Bemiparin in Neonatal Thrombosis: Therapeutic Dosing and Safety","volume":"45","author":"Sampedro","year":"2024","journal-title":"J. Perinatol."},{"key":"ref_91","first-page":"950","article-title":"Update on Low Molecular Weight Heparins at the Beginning of Third Millennium. Focus on Reviparin","volume":"15","author":"Martini","year":"2011","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1161\/CIRCULATIONAHA.106.620880","article-title":"Acute Pulmonary Embolism\u2014Part II: Treatment and Prophylaxis","volume":"114","author":"Piazza","year":"2006","journal-title":"Circulation"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/1076029614564863","article-title":"Should Low-Molecular-Weight Heparin Be Preferred Over Unfractionated Heparin After Thrombolysis for Severity Pulmonary Embolism?","volume":"22","author":"Senturk","year":"2015","journal-title":"Clin. Appl. Thromb."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Lazrak, H.H., Ren\u00e9, \u00c9., Elftouh, N., Leblanc, M., and Lafrance, J.P. (2017). Safety of Low-Molecular-Weight Heparin Compared to Unfractionated Heparin in Hemodialysis: A Systematic Review and Meta-Analysis. BMC Nephrol., 18.","DOI":"10.1186\/s12882-017-0596-4"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/ckj\/sfw049","article-title":"Low-Molecular Weight Heparin Infusion as Anticoagulation for Haemodialysis","volume":"9","author":"Wong","year":"2016","journal-title":"Clin. Kidney J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/bs.pmbts.2019.02.003","article-title":"Low Molecular Weight Heparins and Their Clinical Applications","volume":"163","author":"Hao","year":"2019","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_97","unstructured":"(2022, June 30). UW Medicine\u2014Low Molecular Weight Heparin Dosing Recommendations. Available online: http:\/\/depts.washington.edu\/anticoag\/home\/sites\/default\/files\/LMWH_Dosing_Recommendations_March_2013.pdf."},{"key":"ref_98","first-page":"e20240149","article-title":"Enoxaparin Versus Unfractionated Heparin in Acute Coronary Syndrome Without St-Segment Elevation: A Systematic Review and Meta-Analysis","volume":"38","author":"Bertoli","year":"2025","journal-title":"Int. J. Cardiovasc. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2141.2006.05959.x","article-title":"Low-Molecular Weight and Unfractionated Heparins Induce a Downregulation of Inflammation: Decreased Levels of Proinflammatory Cytokines and Nuclear Factor-\u039aB in LPS-Stimulated Human Monocytes","volume":"133","author":"Hochart","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/pr.115.011247","article-title":"Pharmacology of Heparin and Related Drugs","volume":"68","author":"Mulloy","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Li, Z., and Li, Z. (2025). Development of the Anticoagulant Drug Fondaparinux Sodium. Medicinal Chemistry and Drug Development, Elsevier.","DOI":"10.1016\/B978-0-443-27402-2.00014-0"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1161\/01.ATV.0000084827.77945.66","article-title":"Emerging Anticoagulant Drugs","volume":"23","author":"Bates","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/ecp.09.55","article-title":"Idraparinux and Idrabiotaparinux","volume":"3","author":"Harenberg","year":"2010","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1538-7836.2008.02943.x","article-title":"Long Elimination Half-Life of Idraparinux May Explain Major Bleeding and Recurrent Events of Patients from the van Gogh Trials","volume":"6","author":"Harenberg","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Song, Y., Li, X., Pavithra, S., and Li, D. (2013). Idraparinux or Idrabiotaparinux for Long-Term Venous Thromboembolism Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0078972"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1538-7836.2010.04100.x","article-title":"Efficacy and Safety of Once Weekly Subcutaneous Idrabiotaparinux in the Treatment of Patients with Symptomatic Deep Venous Thrombosis","volume":"9","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1172\/JCI200318234","article-title":"Heparan Sulfate: Antithrombotic or Not?","volume":"111","author":"Weitz","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Kim, H.N., Whitelock, J.M., and Lord, M.S. (2017). Structure-Activity Relationships of Bioengineered Heparin\/Heparan Sulfates Produced in Different Bioreactors. Molecules, 22.","DOI":"10.3390\/molecules22050806"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3892\/mmr.2014.2025","article-title":"Direct Thrombin Inhibitors: Patents 2002\u20132012 (Review)","volume":"9","author":"Kong","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.beha.2004.03.008","article-title":"Small-Molecule Direct Antithrombins: Argatroban","volume":"17","author":"Fareed","year":"2004","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.clinthera.2010.04.012","article-title":"Rationale and Design of the PREVENT-HIT Study: A Randomized, Open-Label Pilot Study to Compare Desirudin and Argatroban in Patients with Suspected Heparin-Induced Thrombocytopenia with or without Thrombosis","volume":"32","author":"Frame","year":"2010","journal-title":"Clin. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1161\/01.CIR.0000096056.37269.14","article-title":"Anaphylactic and Anaphylactoid Reactions Associated with Lepirudin in Patients with Heparin-Induced Thrombocytopenia","volume":"108","author":"Greinacher","year":"2003","journal-title":"Circulation"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.2146\/sp150018","article-title":"Comparison of Bivalirudin to Lepirudin and Argatroban in Patients with Heparin-Induced Thrombocytopenia","volume":"72","author":"Bain","year":"2015","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/joim.12138","article-title":"Advantages and Limitations of the New Anticoagulants","volume":"275","author":"Schulman","year":"2014","journal-title":"J. Intern. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"ref_116","first-page":"CD010957","article-title":"Oral Direct Thrombin Inhibitors or Oral Factor Xa Inhibitors for the Treatment of Pulmonary Embolism","volume":"2015","author":"Robertson","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1056\/NEJMoa2509426","article-title":"Apixaban for Extended Treatment of Provoked Venous Thromboembolism","volume":"393","author":"Piazza","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14740338.2025.2462652","article-title":"Rivaroxaban to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Narrative Review","volume":"24","author":"Roy","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s11239-018-1752-9","article-title":"Direct Oral Anticoagulants: A Review of Common Medication Errors","volume":"47","author":"Barr","year":"2019","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"432","DOI":"10.5694\/j.1326-5377.2004.tb06367.x","article-title":"The Direct Thrombin Inhibitor Melagatran\/Ximelagatran","volume":"181","author":"Brighton","year":"2004","journal-title":"Med. J. Aust."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus Warfarin in Patients with Atrial Fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus Warfarin in Patients with Atrial Fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_125","unstructured":"(2022, June 30). Warfarin\u2014StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470313\/."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.05.032","article-title":"Effects of Anti-Vitamin k Oral Anticoagulants on Bone and Cardiovascular Health","volume":"79","author":"Marietta","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Maniscalco, L., Varello, K., Zoppi, S., Abbamonte, G., Ferrero, M., Torres, E., Ostorero, F., Rossi, F., and Bozzetta, E. (2021). Abnormal Prothrombin (Pivka-ii) Expression in Canine Tissues as an Indicator of Anticoagulant Poisoning. Animals, 11.","DOI":"10.3390\/ani11092612"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/asheducation-2018.1.332","article-title":"Optimizing Quality Care for the Oral Vitamin K Antagonists (VKAs)","volume":"2018","author":"Pengo","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/asheducation-2016.1.413","article-title":"The Post-Thrombotic Syndrome","volume":"2016","author":"Kahn","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_130","first-page":"E156","article-title":"Dual Anticoagulation with Fondaparinux and Dabigatran for Treatment of Cancer-Associated Hypercoagulability","volume":"93","author":"Connors","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12959-016-0089-x","article-title":"Extensive Deep Vein Thrombosis Treatment Using Fondaparinux and Edoxaban: A Case Report","volume":"14","author":"Shimizu","year":"2016","journal-title":"Thromb. J."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"516","DOI":"10.5694\/mja2.50201","article-title":"Deep Vein Thrombosis: Update on Diagnosis and Management","volume":"210","author":"Kruger","year":"2019","journal-title":"Med. J. Aust."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/jth.14324","article-title":"Sulodexide in Venous Disease","volume":"17","author":"Carroll","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","article-title":"Clinical Practice Guideline Document Editor\u2019s Choice-European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis","volume":"61","author":"Kakkos","year":"2021","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_135","first-page":"S376","article-title":"Overview of Venous Thromboembolism","volume":"23","author":"Haiey","year":"2017","journal-title":"Am. J. Manag. Care"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1161\/ATVBAHA.120.315754","article-title":"Thrombus Structural Composition in Cardiovascular Disease","volume":"41","author":"Alkarithi","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/imj.14145","article-title":"Acute Pulmonary Embolism: A Concise Review of Diagnosis and Management","volume":"49","author":"Darvall","year":"2019","journal-title":"Intern. Med. J."},{"key":"ref_138","first-page":"CD010222","article-title":"Anticoagulant Treatment for Subsegmental Pulmonary Embolism","volume":"2020","author":"Yoo","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2174\/1381612822666161221145614","article-title":"Oral Antiplatelet and Anticoagulant Agents in the Prevention and Management of Ischemic Stroke","volume":"23","author":"Shrestha","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1177\/2047487316682349","article-title":"Cerebrovascular Disease, Associated Risk Factors and Antithrombotic Therapy in a Population Screening Cohort: Insights from the Belgian Heart Rhythm Week Programme","volume":"24","author":"Proietti","year":"2017","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-Analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/1076029616660762","article-title":"Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke","volume":"23","author":"Kapil","year":"2017","journal-title":"Clin. Appl. Thromb."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/STROKEAHA.116.016327","article-title":"Restarting Anticoagulant Therapy After Intracranial Hemorrhage: A Systematic Review and Meta-Analysis","volume":"48","author":"Murthy","year":"2017","journal-title":"Stroke"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood-2014-09-599498","article-title":"Fondaparinux for the Treatment of Suspected Heparin-Induced Thrombocytopenia: A Propensity Score\u2013Matched Study","volume":"125","author":"Kang","year":"2015","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"ehab724.2982","DOI":"10.1093\/eurheartj\/ehab724.2982","article-title":"Dabigatran as First-Line Treatment for Heparin-Induced Thrombocytopenia in the Intensive Cardiac Care Setting","volume":"42","author":"Szyda","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Carr\u00e9, J., Jourdi, G., Gendron, N., Helley, D., Gaussem, P., and Darnige, L. (2022). Recent Advances in Anticoagulant Treatment of Immune Thrombosis: A Focus on Direct Oral Anticoagulants in Heparin-Induced Thrombocytopenia and Anti-Phospholipid Syndrome. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010093"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e12236","DOI":"10.1097\/MD.0000000000012236","article-title":"Fondaparinux in a Critically Ill Patient with Heparin-Induced Thrombocytopenia: A Case Report","volume":"97","author":"He","year":"2018","journal-title":"Medicine"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/rth2.12145","article-title":"Systematic Review of Fondaparinux for Heparin-Induced Thrombocytopenia: When There Are No Randomized Controlled Trials","volume":"2","author":"Linkins","year":"2018","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Carr\u00e9, J., Gu\u00e9rineau, H., Le Beller, C., Mauge, L., Huynh, B., Nili, R., Planquette, B., Clauser, S., Smadja, D.M., and Helley, D. (2021). Direct Oral Anticoagulants as Successful Treatment of Heparin-Induced Thrombocytopenia: A Parisian Retrospective Case Series. Front. Med., 8.","DOI":"10.3389\/fmed.2021.713649"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood.2020004942","article-title":"How I Treat Anticoagulant-Refractory Thrombotic Antiphospholipid Syndrome","volume":"137","author":"Cohen","year":"2021","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"714","DOI":"10.6004\/jnccn.2011.0062","article-title":"Venous Thromboembolic Disease","volume":"9","author":"Streiff","year":"2011","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients with Cancer: A Randomized Clinical Trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMA"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Schl\u00f6mmer, C., Brandtner, A., and Bachler, M. (2021). Antithrombin and Its Role in Host Defense and Inflammation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084283"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Rochette, L., and Ghibu, S. (2021). Mechanics Insights of Alpha-Lipoic Acid against Cardiovascular Diseases during COVID-19 Infection. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22157979"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/jth.14810","article-title":"ISTH Interim Guidance on Recognition and Management of Coagulopathy in COVID-19","volume":"18","author":"Thachil","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"10321","DOI":"10.1038\/s41598-024-77858-w","article-title":"Assessing Differential Application of Thromboprophylaxis Regimes Related to Risk of Pulmonary Embolism and Mortality in COVID-19 Patients through Instrumental Variable Analysis","volume":"15","author":"Nab","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.chest.2020.05.559","article-title":"Prevention, Diagnosis, and Treatment of VTE in Patients with Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report","volume":"158","author":"Moores","year":"2020","journal-title":"Chest"},{"key":"ref_158","unstructured":"(2026, January 11). COVID-19: Hypercoagulability\u2014UpToDate. Available online: https:\/\/www.uptodate.com\/contents\/covid-19-hypercoagulability?search=vtecovid&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1097\/HS9.0000000000000526","article-title":"DOAC in COVID-19: Yes or No?","volume":"5","author":"Schutgens","year":"2021","journal-title":"HemaSphere"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3325\/cmj.2022.63.287","article-title":"The Role of Direct Oral Anticoagulants in the Era of COVID-19: Are Antiviral Therapy and Pharmacogenetics Limiting Factors?","volume":"63","author":"Kuna","year":"2022","journal-title":"Croat. Med. J."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1111\/jth.15809","article-title":"Good Practice Statements for Antithrombotic Therapy in the Management of COVID-19: Guidance from the SSC of the ISTH","volume":"20","author":"Spyropoulos","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/clc.23196","article-title":"Anticoagulation in Chronic Kidney Disease: From Guidelines to Clinical Practice","volume":"42","author":"Aursulesei","year":"2019","journal-title":"Clin. Cardiol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.amjmed.2017.06.004","article-title":"Renal Function and Direct Oral Anticoagulant Treatment for Venous Thromboembolism","volume":"130","author":"Fanikos","year":"2017","journal-title":"Am. J. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.ajkd.2021.02.328","article-title":"Oral Anticoagulant Agents in Patients with Atrial Fibrillation and CKD: A Systematic Review and Pairwise Network Meta-Analysis","volume":"78","author":"Su","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/phar.1905","article-title":"Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment","volume":"37","author":"Stanton","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40620-019-00592-4","article-title":"Anticoagulation in CKD and ESRD","volume":"32","author":"Leung","year":"2019","journal-title":"J. Nephrol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/8755122514567316","article-title":"Safety and Efficacy of Fondaparinux in Renal Impairment","volume":"31","author":"Ibrahim","year":"2015","journal-title":"J. Pharm. Technol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/liv.13882","article-title":"In Vitro Efficacy of Pro- and Anticoagulant Strategies in Compensated and Acutely Ill Patients with Cirrhosis","volume":"38","author":"Lisman","year":"2018","journal-title":"Liver Int."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.jacc.2018.03.023","article-title":"Oral Anticoagulation in Patients with Liver Disease","volume":"71","author":"Qamar","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"339","DOI":"10.14218\/JCTH.2021.00268","article-title":"Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications","volume":"10","author":"Ogresta","year":"2022","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/j.gastro.2019.03.070","article-title":"AGA Clinical Practice Update: Coagulation in Cirrhosis","volume":"157","author":"Greenberg","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e006212","DOI":"10.1161\/CIRCOUTCOMES.119.006212","article-title":"Net Clinical Benefit of Oral Anticoagulation among Older Adults with Atrial Fibrillation","volume":"12","author":"Shah","year":"2019","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1055\/a-1174-1290","article-title":"Management of Anticoagulant Treatment and Anticoagulation-Related Complications in Nonagenarians","volume":"40","author":"Giustozzi","year":"2020","journal-title":"Hamostaseologie"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.117.031658","article-title":"Oral Anticoagulation in Very Elderly Patients with Atrial Fibrillation","volume":"138","author":"Chao","year":"2018","journal-title":"Circulation"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/heartjnl-2020-318753","article-title":"Effectiveness and Safety of Oral Anticoagulants in Elderly Patients with Atrial Fibrillation","volume":"108","author":"Rutherford","year":"2022","journal-title":"Heart"},{"key":"ref_176","first-page":"17","article-title":"Treating Atrial Fibrillation in Very Old Patients with New Oral Anticoagulation Drugs: Arguments pro and Contra","volume":"17","author":"Toader","year":"2019","journal-title":"Eur. J. Cardiol. Pract."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.114.003902","article-title":"Cardiovascular Management in Pregnancy","volume":"132","author":"Yarrington","year":"2015","journal-title":"Circulation"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.jacc.2016.06.076","article-title":"Anticoagulation During Pregnancy Evolving Strategies with a Focus on Mechanical Valves","volume":"68","author":"Alshawabkeh","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u039aB Signaling in Inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"549417","DOI":"10.1155\/2015\/549417","article-title":"Diverse Roles of Heparan Sulfate and Heparin in Wound Repair","volume":"2015","author":"Olczyk","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"ref_181","first-page":"224","article-title":"Effects of Heparin on Wound Healing","volume":"23","author":"Galvan","year":"1996","journal-title":"J. Wound Ostomy Cont. Nurs."},{"key":"ref_182","first-page":"e3157","article-title":"Role of Heparin Irrigation in the Management of Superficial Burns with Special Reference to Pain Relief and Wound Healing: A Pilot Study","volume":"10","author":"Vijayakumar","year":"2018","journal-title":"Cureus"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"110923","DOI":"10.1016\/j.msec.2020.110923","article-title":"Antibacterial Polypeptide\/Heparin Composite Hydrogels Carrying Growth Factor for Wound Healing","volume":"112","author":"Hsu","year":"2020","journal-title":"Mater. Sci. Eng. C. Mater. Biol. Appl."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.burns.2018.05.010","article-title":"Comparative Study of Conventional and Topical Heparin Treatment in Second Degree Burn Patients for Burn Analgesia and Wound Healing","volume":"45","author":"Manzoor","year":"2019","journal-title":"Burns"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Andrgie, A.T., Darge, H.F., Mekonnen, T.W., Birhan, Y.S., Hanurry, E.Y., Chou, H.Y., Wang, C.F., Tsai, H.C., Yang, J.M., and Chang, Y.H. (2020). Ibuprofen-Loaded Heparin Modified Thermosensitive Hydrogel for Inhibiting Excessive Inflammation and Promoting Wound Healing. Polymers, 12.","DOI":"10.3390\/polym12112619"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"111169","DOI":"10.1016\/j.msec.2020.111169","article-title":"In Situ Hydrogel Dressing Loaded with Heparin and Basic Fibroblast Growth Factor for Accelerating Wound Healing in Rat","volume":"116","author":"Peng","year":"2020","journal-title":"Mater. Sci. Eng. C. Mater. Biol. Appl."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1590\/S0102-86502012000900009","article-title":"Comparison of Effects of Unfractionated Heparin and Low Molecular Weight Heparin on Skin Wound Healing of Rats","volume":"27","author":"Durmaz","year":"2012","journal-title":"Acta Cir. Bras."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"110498","DOI":"10.1016\/j.biopha.2020.110498","article-title":"Chitosan Hydrogels Functionalized with Either Unfractionated Heparin or Bemiparin Improve Diabetic Wound Healing","volume":"129","author":"Cifuentes","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"e1911","DOI":"10.1097\/MJT.0000000000000251","article-title":"Low-Molecular-Weight Heparins as Immunomodulators in Dermatology Practice","volume":"23","author":"Solak","year":"2016","journal-title":"Am. J. Ther."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"44","DOI":"10.12968\/jowc.2020.29.1.44","article-title":"Effects of Anticoagulant Drugs on Wound Healing Process in a Rat Model: A Comparative Study","volume":"29","author":"Savluk","year":"2020","journal-title":"J. Wound Care"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/jamafacial.2014.1147","article-title":"Anticoagulant Complications in Facial Plastic and Reconstructive Surgery","volume":"17","author":"Kraft","year":"2015","journal-title":"JAMA Facial Plast. Surg."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"L211","DOI":"10.1152\/ajplung.00199.2020","article-title":"Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities","volume":"319","author":"Hippensteel","year":"2020","journal-title":"Am. J. Physiol.\u2014Lung Cell. Mol. Physiol."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Chis, A.A., Arseniu, A.M., Morgovan, C., Dobrea, C.M., Frum, A., Juncan, A.M., Butuca, A., Ghibu, S., Gligor, F.G., and Rus, L.L. (2022). Biopolymeric Prodrug Systems as Potential Antineoplastic Therapy. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14091773"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.carbpol.2015.12.007","article-title":"The Synthesis and Application of Heparin-Based Smart Drug Carrier","volume":"140","author":"Li","year":"2016","journal-title":"Carbohydr. Polym."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Andrgie, A.T., Birhan, Y.S., Mekonnen, T.W., Hanurry, E.Y., Darge, H.F., Lee, R.H., Chou, H.Y., and Tsai, H.C. (2019). Redox-Responsive Heparin\u2013Chlorambucil Conjugate Polymeric Prodrug for Improved Anti-Tumor Activity. Polymers, 12.","DOI":"10.3390\/polym12010043"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1504\/IJNT.2018.089566","article-title":"Thermosensitive Heparin-Pluronic\u00ae Copolymer as Effective Dual Anticancer Drugs Delivery System for Combination Cancer Therapy","volume":"15","author":"Tong","year":"2018","journal-title":"Int. J. Nanotechnol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijbiomac.2019.05.031","article-title":"The Utilization of Low Molecular Weight Heparin-Poloxamer Associated Laponite Nanoplatform for Safe and Efficient Tumor Therapy","volume":"134","author":"Li","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.7326\/M21-1094","article-title":"Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism: A Systematic Review and Meta-Analysis","volume":"174","author":"Khan","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(16)30162-5","article-title":"Risk of Gastrointestinal Bleeding with Direct Oral Anticoagulants: A Systematic Review and Network Meta-Analysis","volume":"2","author":"Burr","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1631\/jzus.B1600143","article-title":"Risk Analysis of New Oral Anticoagulants for Gastrointestinal Bleeding and Intracranial Hemorrhage in Atrial Fibrillation Patients: A Systematic Review and Network Meta-Analysis","volume":"18","author":"Xu","year":"2017","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1055\/s-0033-1357506","article-title":"Intracerebral Bleeding in Patients on Antithrombotic Agents","volume":"39","author":"Veltkamp","year":"2013","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1358863X18819816","article-title":"Anticoagulation Risk Assessment for Patients with Non-Valvular Atrial Fibrillation and Venous Thromboembolism: A Clinical Review","volume":"24","author":"Pallazola","year":"2019","journal-title":"Vasc. Med."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1055\/s-0037-1598061","article-title":"Scoring Systems for Estimating the Risk of Anticoagulant-Associated Bleeding","volume":"43","author":"Parks","year":"2017","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/jth.14131","article-title":"A Systematic Review and Bayesian Network Meta-Analysis of Risk of Intracranial Hemorrhage with Direct Oral Anticoagulants","volume":"16","author":"Wolfe","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s00415-021-10448-2","article-title":"Risk of Intracranial Hemorrhage with Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"269","author":"Wu","year":"2022","journal-title":"J. Neurol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5603\/KP.a2018.0197","article-title":"How Can We Reverse Bleeding in Patients on Direct Oral Anticoagulants?","volume":"77","author":"Crowther","year":"2019","journal-title":"Kardiol. Pol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/1076029616675970","article-title":"Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants","volume":"23","author":"Dhakal","year":"2017","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"E736","DOI":"10.1503\/cmaj.210637","article-title":"Heparin-Induced Thrombocytopenia","volume":"193","author":"Jevtic","year":"2021","journal-title":"Can. Med. Assoc. J."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/pgmj.2007.059188","article-title":"Heparin Induced Thrombocytopenia: Diagnosis and Management Update","volume":"83","author":"Ahmed","year":"2007","journal-title":"Postgrad. Med. J."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1398-9995.2006.01227.x","article-title":"Hypersensitivity Reactions to Anticoagulant Drugs: Diagnosis and Management Options","volume":"61","author":"Bircher","year":"2006","journal-title":"Allergy"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.trsl.2020.04.014","article-title":"Pathogenesis of Heparin-Induced Thrombocytopenia","volume":"225","author":"Arepally","year":"2020","journal-title":"Transl. Res."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/ijlh.12993","article-title":"Laboratory Diagnosis of Heparin-Induced Thrombocytopenia","volume":"41","author":"Warkentin","year":"2019","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/ajh.26194","article-title":"Comparative Effectiveness and Safety of Anticoagulants for the Treatment of Heparin-Induced Thrombocytopenia","volume":"96","author":"Nilius","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/0897190019882866","article-title":"Argatroban Versus Bivalirudin in the Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia","volume":"34","author":"Duewell","year":"2021","journal-title":"J. Pharm. Pract."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/17474086.2019.1636645","article-title":"High-Dose Intravenous Immunoglobulin for the Treatment and Prevention of Heparin-Induced Thrombocytopenia: A Review","volume":"12","author":"Warkentin","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/jth.14411","article-title":"High-Dose Intravenous Immunoglobulin to Treat Spontaneous Heparin-Induced Thrombocytopenia Syndrome","volume":"17","author":"Mohanty","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1060028020943542","article-title":"Intravenous Immune Globulin (IVIG) for Treatment of Autoimmune Heparin-Induced Thrombocytopenia: A Systematic Review","volume":"55","author":"Dougherty","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/ACI.0000000000000281","article-title":"Hypersensitivity Reactions to Heparins","volume":"16","author":"Fernandez","year":"2016","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s40629-015-0048-2","article-title":"Hypersensitivity Reactions to Modern Antiplatelet and Anticoagulant Drugs","volume":"24","author":"Hofmeier","year":"2015","journal-title":"Allergo J. Int."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1046\/j.1365-2168.2000.01352.x","article-title":"Warfarin Induced Skin Necrosis","volume":"87","author":"Chan","year":"2000","journal-title":"Br. J. Surg."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jaad.2008.12.039","article-title":"Warfarin-Induced Skin Necrosis","volume":"61","author":"Nazarian","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00380-006-0935-z","article-title":"Warfarin-Induced Skin Necrosis after Open Heart Surgery Due to Protein S and C Deficiency","volume":"22","author":"Oz","year":"2007","journal-title":"Heart Vessel."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/MCA.0b013e328361b388","article-title":"Safety and Feasibility of Intra-Arterial Bivalirudin Bolus Administration during Primary Angioplasty","volume":"24","author":"Chorzempa","year":"2013","journal-title":"Coron. Artery Dis."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1053\/j.jvca.2018.04.028","article-title":"Randomized Controlled Trial of Heparin Versus Bivalirudin Anticoagulation in Acyanotic Children Undergoing Open Heart Surgery","volume":"32","author":"Hasija","year":"2018","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"7","DOI":"10.23822\/EurAnnACI.1764-1489.80","article-title":"Hypersensitivity Reactions to Non-Vitamin K Oral Anticoagulants\u2014A Review of Literature and Diagnostic Work-up Proposal","volume":"51","author":"Carli","year":"2019","journal-title":"Eur. Ann. Allergy Clin. Immunol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1051\/ject\/200638307","article-title":"Heparin Sensitivity Test for Patients Requiring Cardiopulmonary Bypass","volume":"38","author":"DeBois","year":"2006","journal-title":"J. Extracorpor. Technol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s11239-020-02259-5","article-title":"Differentiating Biochemical from Clinical Heparin Resistance in COVID-19","volume":"50","author":"Lisman","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/bja\/88.4.467","article-title":"Editorial I: Heparin Resistance","volume":"88","author":"Anderson","year":"2002","journal-title":"Br. J. Anaesth."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/jth.15209","article-title":"A Novel Vitamin K Derived Anticoagulant Tolerant to Genetic Variations of Vitamin K Epoxide Reductase","volume":"19","author":"Chen","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"143","DOI":"10.5482\/HAMO-13-09-0047","article-title":"Comparative Genetics of Warfarin Resistance","volume":"34","author":"Oldenburg","year":"2014","journal-title":"Hamostaseologie"},{"key":"ref_231","doi-asserted-by":"crossref","unstructured":"C\u00eempan, P.L., Chira, R.I., Mocan, M., Anton, F.P., and Farca\u015f, A.D. (2019). Oral Anticoagulant Therapy-When Art Meets Science. J. Clin. Med., 8.","DOI":"10.3390\/jcm8101747"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/j.thromres.2010.06.008","article-title":"VKORC1 V66M Mutation in African Brazilian Patients Resistant to Oral Anticoagulant Therapy","volume":"126","author":"Orsi","year":"2010","journal-title":"Thromb. Res."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1538-7836.2010.04095.x","article-title":"Thirteen Novel VKORC1 Mutations Associated with Oral Anticoagulant Resistance: Insights into Improved Patient Diagnosis and Treatment","volume":"9","author":"Watzka","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Sobh, M.M., Abdalbary, M., Elnagar, S., Nagy, E., Elshabrawy, N., Abdelsalam, M., Asadipooya, K., and El-Husseini, A. (2022). Secondary Osteoporosis and Metabolic Bone Diseases. J. Clin. Med., 11.","DOI":"10.3390\/jcm11092382"},{"key":"ref_235","doi-asserted-by":"crossref","unstructured":"M\u00e1rquez-Grant, N., Baldini, E., Jeynes, V., Biehler-Gomez, L., Aoukhiyad, L., Passalacqua, N.V., Giordano, G., Di Candia, D., and Cattaneo, C. (2022). How Do Drugs Affect the Skeleton? Implications for Forensic Anthropology. Biology, 11.","DOI":"10.3390\/biology11040524"},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Signorelli, S.S., Scuto, S., Marino, E., Giusti, M., Xourafa, A., and Gaudio, A. (2019). Anticoagulants and Osteoporosis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215275"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"e20.00194","DOI":"10.2106\/JBJS.RVW.20.00194","article-title":"Effects of Anticoagulant Medication on Bone-Healing","volume":"9","author":"Butler","year":"2021","journal-title":"JBJS Rev."},{"key":"ref_238","doi-asserted-by":"crossref","unstructured":"Palmirotta, R. (2022). Direct Oral Anticoagulants (DOAC): Are We Ready for a Pharmacogenetic Approach?. J. Pers. Med., 12.","DOI":"10.3390\/jpm12010017"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2165\/00003088-199630060-00002","article-title":"Clinically Important Drug Interactions with Anticoagulants. An Update","volume":"30","author":"Harder","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jons.2018.06.001","article-title":"A Retrospective Study on Potential Drug Interactions: A Single Center Experience","volume":"4","author":"Korucu","year":"2018","journal-title":"J. Oncol. Sci."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00003088-200241002-00005","article-title":"Absence of Interaction of Fondaparinux Sodium with Aspirin and Piroxicam in Healthy Male Volunteers","volume":"41","author":"Ollier","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/jcpt.13391","article-title":"Adverse Drug Reactions with Oral Anticoagulants: Data from Sicilian Spontaneous Reporting System Database","volume":"46","author":"Barbieri","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2147\/TCRM.S84210","article-title":"New Oral Anticoagulants: Their Advantages and Disadvantages Compared with Vitamin K Antagonists in the Prevention and Treatment of Patients with Thromboembolic Events","volume":"11","author":"Mekaj","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s11239-011-0561-1","article-title":"Drug and Dietary Interactions of Warfarin and Novel Oral Anticoagulants: An Update","volume":"31","author":"Nutescu","year":"2011","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/jth.13268","article-title":"The Effect of Carbamazepine on Warfarin Anticoagulation: A Register-Based Nationwide Cohort Study Involving the Swedish Population","volume":"14","author":"Mannheimer","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1592\/phco.24.9.945.36100","article-title":"Azithromycin and Warfarin Interaction","volume":"24","author":"Shrader","year":"2004","journal-title":"Pharmacotherapy"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1111\/bcp.14833","article-title":"Drug-Drug Interactions with Warfarin: A Systematic Review and Meta-Analysis","volume":"87","author":"Wang","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/blood-2018-06-848747","article-title":"Drug-Drug Interactions in an Era of Multiple Anticoagulants: A Focus on Clinically Relevant Drug Interactions","volume":"132","author":"Vazquez","year":"2018","journal-title":"Blood"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.blre.2017.02.001","article-title":"Old and New Oral Anticoagulants: Food, Herbal Medicines and Drug Interactions","volume":"31","author":"Frigerio","year":"2017","journal-title":"Blood Rev."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/030006059902700402","article-title":"Acute Effects of Griseofulvin on the Pharmacokinetics and Pharmacodynamics of Warfarin in Rats","volume":"27","author":"Matsumura","year":"1999","journal-title":"J. Int. Med. Res."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40064-015-1653-8","article-title":"Rifampin-Warfarin Interaction in a Mitral Valve Replacement Patient Receiving Rifampin for Infective Endocarditis: A Case Report","volume":"5","author":"Fahmi","year":"2016","journal-title":"Springerplus"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1503\/cmaj.1070121","article-title":"Antiepileptic Drugs and Warfarin","volume":"178","author":"Ahmed","year":"2008","journal-title":"Can. Med. Assoc. J."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic Overview of Warfarin and Its Drug and Food Interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_254","first-page":"1061","article-title":"Adverse Drug Reactions and Drug\u2013 Drug Interactions with over-the-Counter NSAIDs","volume":"11","author":"Moore","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3346\/jkms.2010.25.3.337","article-title":"Risk Factors of Drug Interaction between Warfarin and Nonsteroidal Anti-Inflammatory Drugs in Practical Setting","volume":"25","author":"Choi","year":"2010","journal-title":"J. Korean Med. Sci."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2125.1983.tb02239.x","article-title":"Phenylbutazone-Warfarin Interaction in Man: Further Stereochemical and Metabolic Considerations","volume":"16","author":"Banfield","year":"1983","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/0090-4295(80)90568-3","article-title":"Potentiation of Warfarin by Trimethoprim-Sulfamethoxazole","volume":"16","author":"Kaufman","year":"1980","journal-title":"Urology"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jiac.2020.07.014","article-title":"Comparison of Interactions between Warfarin and Cephalosporins with and without the N-Methyl-Thio-Tetrazole Side Chain","volume":"26","author":"Imai","year":"2020","journal-title":"J. Infect. Chemother."},{"key":"ref_259","unstructured":"(2022, August 01). Warfarin Drug Interactions\u2014StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK441964\/."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00003088-200342010-00003","article-title":"Role of P-Glycoprotein in Pharmacokinetics: Clinical Implications","volume":"42","author":"Lin","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bcp.14404","article-title":"Warfarin and Food, Herbal or Dietary Supplement Interactions: A Systematic Review","volume":"87","author":"Tan","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_262","doi-asserted-by":"crossref","unstructured":"Yu, C.-P., Yang, M.-S., Hsu, P.-W., Lin, S.-P., and Hou, Y.-C. (2021). Bidirectional Influences of Cranberry on the Pharmacokinetics and Pharmacodynamics of Warfarin with Mechanism Elucidation. Nutrients, 13.","DOI":"10.3390\/nu13093219"},{"key":"ref_263","doi-asserted-by":"crossref","unstructured":"Heghes, S.C., Vostinaru, O., Mogosan, C., Miere, D., Iuga, C.A., and Filip, L. (2022). Safety Profile of Nutraceuticals Rich in Coumarins: An Update. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.803338"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"32","DOI":"10.18773\/austprescr.2016.025","article-title":"Warfarin, St John\u2019s Wort and INR","volume":"39","author":"Cattanach","year":"2016","journal-title":"Aust. Prescr."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"146S","DOI":"10.1592\/phco.24.12.146S.36107","article-title":"Unfractionated Heparin: Focus on a High-Alert Drug","volume":"24","author":"Niccolai","year":"2004","journal-title":"Pharmacotherapy"},{"key":"ref_266","first-page":"195","article-title":"Harmful Medication Errors Involving Unfractionated and Low-Molecular-Weight Heparin in Three Patient Safety Reporting Programs","volume":"36","author":"Grissinger","year":"2010","journal-title":"Jt. Comm. J. Qual. Patient Saf."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"731","DOI":"10.4338\/ACI-2016-01-RA-0010","article-title":"Renal Drug Dosing: Effectiveness of Outpatient Pharmacist-Based vs. Prescriber-Based Clinical Decision Support Systems","volume":"7","author":"Vogel","year":"2016","journal-title":"Appl. Clin. Inform."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4081\/cp.2016.873","article-title":"Medication Error When Switching from Warfarin to Rivaroxaban Leading to Spontaneous Large Ecchymosis of the Abdominal and Chest Wall","volume":"6","author":"Egger","year":"2016","journal-title":"Clin. Pract."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00228-012-1358-7","article-title":"Identification and Weighting of the Most Critical \u201cReal-Life\u201d Drug-Drug Interactions with Acenocoumarol in a Tertiary Care Hospital","volume":"69","author":"Gschwind","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/IJGM.S129235","article-title":"Utilization and Prescribing Patterns of Direct Oral Anticoagulants","volume":"10","author":"Whitworth","year":"2017","journal-title":"Int. J. Gen. Med."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s11239-017-1487-z","article-title":"Appropriateness of Direct Oral Anticoagulant Dosing for Venous Thromboembolism Treatment","volume":"43","author":"Tran","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jamainternmed.2014.946","article-title":"Bleeding Risk of Patients with Acute Venous Thromboembolism Taking Nonsteroidal Anti-Inflammatory Drugs or Aspirin","volume":"174","author":"Davidson","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40264-016-0443-8","article-title":"Drug Interactions of Direct-Acting Oral Anticoagulants","volume":"39","author":"Fitzgerald","year":"2016","journal-title":"Drug Saf."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11239-017-1585-y","article-title":"Oral Anticoagulant Dosing, Administration, and Storage: A Cross-Sectional Survey of Canadian Health Care Providers","volume":"45","author":"Piran","year":"2018","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"e00307","DOI":"10.1002\/prp2.307","article-title":"Medication Errors Involving Anticoagulants: Data from the Danish Patient Safety Database","volume":"5","author":"Henriksen","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/AAP.0000000000000763","article-title":"Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition)","volume":"43","author":"Horlocker","year":"2018","journal-title":"Reg. Anesth. Pain Med."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40545-021-00369-w","article-title":"Medication Errors Associated with Direct-Acting Oral Anticoagulants: Analysis of Data from National Pharmacovigilance and Local Incidents Reporting Databases","volume":"14","author":"Alrowily","year":"2021","journal-title":"J. Pharm. Policy Pract."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s11096-021-01302-6","article-title":"Direct Oral Anticoagulant-Related Medication Incidents and Pharmacists\u2019 Interventions in Hospital in-Patients: Evaluation Using Reason\u2019s Accident Causation Theory","volume":"43","author":"Haque","year":"2021","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ajh.27595","article-title":"Therapeutic Errors Associated with Antithrombotic Medications Reported to United States Poison Centers","volume":"100","author":"Cravo","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.amjcard.2020.12.062","article-title":"Inappropriate Dosing of Direct Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"144","author":"Sugrue","year":"2021","journal-title":"Am. J. Cardiol."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/bcp.14264","article-title":"Quality of Clinical Direct Oral Anticoagulant Prescribing and Identification of Risk Factors for Inappropriate Prescriptions","volume":"86","author":"Zhang","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_283","doi-asserted-by":"crossref","unstructured":"Morgovan, C., Dobrea, C.M., Chis, A.A., Juncan, A.M., Arseniu, A.M., Rus, L.L., Gligor, F.G., Ardelean, S.A., Stoicescu, L., and Ghibu, S. (2023). A Descriptive Analysis of Direct Oral Anticoagulant Drugs Dosing Errors Based on Spontaneous Reports from the EudraVigilance Database. Pharmaceuticals, 16.","DOI":"10.3390\/ph16030455"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s40266-019-00710-8","article-title":"Burden of Inappropriate Prescription of Direct Oral Anticoagulants at Hospital Admission and Discharge in the Elderly: A Prospective Observational Multicenter Study","volume":"36","author":"Bruneau","year":"2019","journal-title":"Drugs Aging"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.3399\/bjgp20X714005","article-title":"Inappropriate Direct Oral Anticoagulant Prescriptions in Patients with Non-Valvular Atrial Fibrillation: Cross-Sectional Analysis of the French CACAO Cohort Study in Primary Care","volume":"71","author":"Ferrat","year":"2021","journal-title":"Br. J. Gen. Pract."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2044.1990.tb14316.x","article-title":"Blackout during Cardiopulmonary Bypass","volume":"45","author":"Greenhalgh","year":"1990","journal-title":"Anaesthesia"},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.pharma.2022.02.009","article-title":"Analyse Des Pratiques de Prescription de l\u2019h\u00e9parine Sodique Au Pousse-Seringue \u00c9lectrique","volume":"80","author":"Breniaux","year":"2022","journal-title":"Ann. Pharm. Fran\u00e7aises"},{"key":"ref_288","first-page":"96","article-title":"Neonatal Heparin Overdose\u2014A Multidisciplinary Team Approach to Medication Error Prevention","volume":"13","author":"Arimura","year":"2008","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/1060028020956271","article-title":"A Systemwide Approach for Navigating the Dilemma of Oral Factor Xa Inhibitor Interference with Unfractionated Heparin Anti-Factor Xa Concentrations","volume":"55","author":"Levito","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11096-020-01101-5","article-title":"Voluntarily Reported Prescribing, Monitoring and Medication Transfer Errors in Intensive Care Units in The Netherlands","volume":"43","author":"Bosma","year":"2021","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/intqhc\/mzy177","article-title":"Anticoagulant Medication Errors in Hospitals and Primary Care: A Cross-Sectional Study","volume":"31","author":"Dreijer","year":"2019","journal-title":"Int. J. Qual. Health Care"},{"key":"ref_292","first-page":"E762","article-title":"Enoxaparin Overdose in a Newborn","volume":"116","author":"Gabriel","year":"2018","journal-title":"Arch. Argent. Pediatr."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1097\/JHQ.0000000000000171","article-title":"Human-Centered Design of a Low Molecular Weight Heparin Order Set to Reduce Medication Errors","volume":"41","author":"Wu","year":"2019","journal-title":"J. Healthc. Qual."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.2146\/ajhp120121","article-title":"Safety and Effectiveness Outcomes of an Inpatient Collaborative Drug Therapy Management Service for Direct Thrombin Inhibitors","volume":"69","author":"Cooper","year":"2012","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.aorn.2017.08.006","article-title":"Situational Awareness and Patient Safety","volume":"106","author":"Farnan","year":"2017","journal-title":"AORN J."},{"key":"ref_296","doi-asserted-by":"crossref","unstructured":"Ghibu, S., Juncan, A.M., Rus, L.L., Frum, A., Dobrea, C.M., Chi\u015f, A.A., Gligor, F.G., and Morgovan, C. (2021). The Particularities of Pharmaceutical Care in Improving Public Health Service during the COVID-19 Pandemic. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18189776"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/jcpt.12816","article-title":"Cancellations of Elective Surgical Procedures Due to Inadequate Management of Chronic Medications","volume":"44","author":"Ribed","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s11739-019-02232-y","article-title":"Correction to: Reversal Agents for Oral Anticoagulant-Associated Major or Life-Threatening Bleeding","volume":"15","author":"Moia","year":"2020","journal-title":"Intern. Emerg. Med."},{"key":"ref_299","unstructured":"(2022, July 29). Andexanet Alfa\u2014StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519499\/."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"314","DOI":"10.7861\/clinmedicine.18-4-314","article-title":"The Reversal of Anticoagulation in Clinical Practice","volume":"18","author":"Thomas","year":"2018","journal-title":"Clin. Med."},{"key":"ref_301","unstructured":"(2022, July 01). Protamine\u2014StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547753\/."},{"key":"ref_302","unstructured":"(2022, July 01). Warfarin Toxicity\u2014StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK431112\/."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"When and How to Use Antidotes for the Reversal of Direct Oral Anticoagulants: Guidance from the SSC of the ISTH","volume":"14","author":"Levy","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(15)60732-2","article-title":"Safety, Tolerability, and Efficacy of Idarucizumab for the Reversal of the Anticoagulant Effect of Dabigatran in Healthy Male Volunteers: A Randomised, Placebo-Controlled, Double-Blind Phase 1 Trial","volume":"386","author":"Glund","year":"2015","journal-title":"Lancet"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for Dabigatran Reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"e12518","DOI":"10.1002\/rth2.12518","article-title":"A Meta-Analysis of Andexanet Alfa and Prothrombin Complex Concentrate in the Treatment of Factor Xa Inhibitor-Related Major Bleeding","volume":"5","author":"Jaspers","year":"2021","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1345\/aph.1Q096","article-title":"Prothrombin Complex Concentrate for Critical Bleeding","volume":"45","author":"Patanwala","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-1-4939-7057-5_2","article-title":"A Protocol for the Preparation of Cryoprecipitate and Cryo-Depleted Plasma for Proteomic Studies","volume":"1619","author":"Sparrow","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/bja\/aeu158","article-title":"Cryoprecipitate Therapy","volume":"113","author":"Nascimento","year":"2014","journal-title":"Br. J. Anaesth."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1161\/CIRCULATIONAHA.111.081489","article-title":"Reversal of Warfarin: Case-Based Practice Recommendations","volume":"125","author":"Garcia","year":"2012","journal-title":"Circulation"},{"key":"ref_311","first-page":"8","article-title":"Tillage Management of Bleeding in Patients Treated with Direct Oral Anticoagulants","volume":"43","author":"HaileSelassie","year":"2018","journal-title":"US Pharmacop."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12959-017-0129-1","article-title":"The Reversal Effect of Prothrombin Complex Concentrate (PCC), Activated PCC and Recombinant Activated Factor VII against Anticoagulation of Xa Inhibitor","volume":"15","author":"Schultz","year":"2017","journal-title":"Thromb. J."},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2019.11.001","article-title":"Potential Usefulness of Activated Charcoal (DOAC Remove\u00ae) for DRVVT Testing in Patients Receiving Direct Oral AntiCoagulants","volume":"184","author":"Jourdi","year":"2019","journal-title":"Thromb. Res."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1515\/cclm-2018-0967","article-title":"Effect of an Activated Charcoal Product (DOAC StopTM) Intended for Extracting DOACs on Various Other APTT-Prolonging Anticoagulants","volume":"57","author":"Exner","year":"2019","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.amjmed.2016.06.009","article-title":"Preclinical and Clinical Data for Factor Xa and \u201cUniversal\u201d Reversal Agents","volume":"129","author":"Milling","year":"2016","journal-title":"Am. J. Med."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.drudis.2012.11.002","article-title":"Low Molecular Weight Heparins Copies: Are They Considered to Be Generics or Biosimilars?","volume":"18","author":"Minghetti","year":"2013","journal-title":"Drug Discov. Today"},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11523-011-0194-5","article-title":"Low Molecular Weight Heparin Biosimilars: How Much Similarity for How Much Clinical Benefit?","volume":"7","author":"Drouet","year":"2012","journal-title":"Target. Oncol."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/14789450.2018.1480110","article-title":"Analysis of Sulfates on Low Molecular Weight Heparin Using Mass Spectrometry: Structural Characterization of Enoxaparin","volume":"15","author":"Gupta","year":"2018","journal-title":"Expert Rev. Proteom."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.thromres.2020.08.016","article-title":"Drug-Drug Interactions with Direct Oral Anticoagulants Associated with Adverse Events in the Real World: A Systematic Review","volume":"194","author":"Li","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_320","doi-asserted-by":"crossref","unstructured":"Bisio, A., Urso, E., Guerrini, M., de Wit, P., Torri, G., and Naggi, A. (2017). Structural Characterization of the Low-Molecular-Weight Heparin Dalteparin by Combining Different Analytical Strategies. Molecules, 22.","DOI":"10.3390\/molecules22071051"},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/DDDT.S162817","article-title":"Bioequivalence of a Biosimilar Enoxaparin Sodium to Clexane \u00ae after Single 100 Mg Subcutaneous Dose: Results of a Randomized, Double-Blind, Crossover Study in Healthy Volunteers","volume":"12","author":"Monreal","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.yrtph.2016.12.003","article-title":"Comparative Subcutaneous Repeated Toxicity Study of Enoxaparin Products in Rats","volume":"84","author":"Kobbi","year":"2017","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1177\/1076029618786583","article-title":"Efficacy and Safety of a Biosimilar Versus Branded Enoxaparin in the Prevention of Venous Thromboembolism Following Major Abdominal Surgery: A Randomized, Prospective, Single-Blinded, Multicenter Clinical Trial","volume":"24","author":"Ramacciotti","year":"2018","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"1076029620960820","DOI":"10.1177\/1076029620960820","article-title":"Comparative Studies on the Anticoagulant Profile of Branded Enoxaparin and a New Biosimilar Version","volume":"26","author":"Qneibi","year":"2020","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ab.2014.02.013","article-title":"Isolation of a Pure Octadecasaccharide with Antithrombin Activity from an Ultra-Low-Molecular-Weight Heparin","volume":"453","author":"Mourier","year":"2014","journal-title":"Anal. Biochem."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/imj.12417","article-title":"Low-Molecular-Weight Heparin Biosimilars: Potential Implications for Clinical Practice. Australian Low-Molecular-Weight Heparin Biosimilar Working Group (ALBW)","volume":"44","author":"Nandurkar","year":"2014","journal-title":"Intern. Med. J."},{"key":"ref_327","unstructured":"(2022, July 01). Heparina Sodica\u2014Rezumatul Caracteristicilor Produsului. Available online: https:\/\/www.anm.ro\/_\/_RCP\/RCP_7534_08.04.15.pdf."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/PAT.0b013e32834bf5f4","article-title":"Laboratory Testing of Anticoagulants: The Present and the Future","volume":"43","author":"Favaloro","year":"2011","journal-title":"Pathology"},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1111\/jth.13489","article-title":"The PiCT\u00ae Test Is a Reliable Alternative to the Activated Partial Thromboplastin Time in Unfractionated Heparin Therapy Management: Results from a Multicenter Study","volume":"14","author":"Brisset","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1515\/CCLM.2011.134","article-title":"Laboratory Assessment of New Anticoagulants","volume":"49","author":"Samama","year":"2011","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/labmed\/lmy054","article-title":"Monitoring Fondaparinux in the Setting of Antithrombin Deficiency","volume":"50","author":"Staley","year":"2019","journal-title":"Lab. Med."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0022-5223(00)70233-9","article-title":"Failure of Danaparoid Anticoagulation for Cardiopulmonary Bypass","volume":"119","author":"Ariano","year":"2000","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0741-5214(98)70336-2","article-title":"Intraoperative Monitoring of Danaparoid Sodium Anticoagulation during Cardiovascular Operations","volume":"27","author":"Gitlin","year":"1998","journal-title":"J. Vasc. Surg."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1345\/aph.1R644","article-title":"Alternative Monitoring of Argatroban Using Plasma-Diluted Thrombin Time","volume":"47","author":"Wanat","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"ref_335","doi-asserted-by":"crossref","unstructured":"Beiderlinden, M., Werner, P., Bahlmann, A., Kemper, J., Brezina, T., Sch\u00e4fer, M., G\u00f6rlinger, K., Seidel, H., Kienbaum, P., and Treschan, T.A. (2018). Monitoring of Argatroban and Lepirudin Anticoagulation in Critically Ill Patients by Conventional Laboratory Parameters and Rotational Thromboelastometry\u2014A Prospectively Controlled Randomized Double-Blind Clinical Trial. BMC Anesthesiol., 18.","DOI":"10.1186\/s12871-018-0475-y"},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/s-0036-1597297","article-title":"Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors","volume":"43","author":"Roberts","year":"2017","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/ijlh.12864","article-title":"Use of D-Dimer in Oral Anticoagulation Therapy","volume":"40","author":"Zhang","year":"2018","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"665","DOI":"10.5858\/arpa.2014-0170-OA","article-title":"Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants","volume":"139","author":"Dias","year":"2015","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"1076029619847524","DOI":"10.1177\/1076029619847524","article-title":"Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum","volume":"25","author":"Siddiqui","year":"2019","journal-title":"Clin. Appl. Thromb."},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/jth.13300","article-title":"A Single Test to Assay Warfarin, Dabigatran, Rivaroxaban, Apixaban, Unfractionated Heparin, and Enoxaparin in Plasma","volume":"14","author":"Letertre","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1373\/49.1.169","article-title":"Comparison of Five Thrombin Time Reagents","volume":"49","author":"Flanders","year":"2003","journal-title":"Clin. Chem."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.chest.2016.08.1462","article-title":"Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review","volume":"151","author":"Samuelson","year":"2017","journal-title":"Chest"},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1177\/0004563215599795","article-title":"Diluted Thrombin Time Reliably Measures Low to Intermediate Plasma Dabigatran Concentrations","volume":"53","author":"Malovrh","year":"2016","journal-title":"Ann. Clin. Biochem."},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/ijlh.12027","article-title":"Preincubation in the Prothrombinase-Induced Clotting Time Test (PiCT) Is Necessary for in Vitro Evaluation of Fondaparinux and to Be Avoided for the Reversible, Direct Factor Xa Inhibitor, Rivaroxaban","volume":"35","author":"Kluft","year":"2013","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_345","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1182\/blood.V122.21.3642.3642","article-title":"Prothrombinase Induced Clotting Time (PICT) and Commercially Available Diluted Russell\u2019s Viper Venom Times For The Monitoring Of New Oral Anticoagulants","volume":"122","author":"Hoppensteadt","year":"2013","journal-title":"Blood"},{"key":"ref_346","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-1-4939-7196-1_14","article-title":"Lupus Anticoagulant Testing: Diluted Russell Viper Venom Time (DRVVT)","volume":"1646","author":"Pengo","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/978-1-62703-339-8_19","article-title":"Anti-Factor Xa (Anti-Xa) Assay","volume":"992","author":"Newall","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1365-2257.1999.00208.x","article-title":"HEPTEST: A Suitable Method for Monitoring Heparin during Pregnancy","volume":"21","author":"Campbell","year":"1999","journal-title":"Clin. Lab. Haematol."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-62703-339-8_12","article-title":"Activated Clotting Time (ACT)","volume":"992","author":"Horton","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000081505","article-title":"The Ecarin Clotting Time, a Universal Method to Quantify Direct Thrombin Inhibitors","volume":"33","author":"Nowak","year":"2003","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/10245332.2001.11746573","article-title":"Thromboelastography","volume":"6","author":"Vig","year":"2022","journal-title":"Hematology"},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"ref_353","doi-asserted-by":"crossref","unstructured":"Legnani, C., Martinelli, I., Palareti, G., Ciavarella, A., Poli, D., Ageno, W., Testa, S., Mastroiacovo, D., Ciammaichella, M., and Bucherini, E. (2019). D-Dimer Levels during and after Anticoagulation Withdrawal in Patients with Venous Thromboembolism Treated with Non-Vitamin K Anticoagulants. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0219751"},{"key":"ref_354","first-page":"261","article-title":"Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux","volume":"43","author":"Babin","year":"2017","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_355","doi-asserted-by":"crossref","unstructured":"Nguyen, T.D., Nguyen, T.N., Nguyen, T.T.T., Ivanov, I.A., Nguyen, K.C., Tran, Q.N., Hoang, A.N., and Utkin, Y.N. (2019). Nanoencapsulation Enhances Anticoagulant Activity of Adenosine and Dipeptide IleTrp. Nanomaterials, 9.","DOI":"10.3390\/nano9091191"},{"key":"ref_356","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1021\/acs.chemrev.1c00631","article-title":"Green Chemistry in the Synthesis of Pharmaceuticals","volume":"122","author":"Kar","year":"2022","journal-title":"Chem. Rev."},{"key":"ref_357","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.ijbiomac.2019.01.222","article-title":"Antimicrobial, Anticoagulant and Antiplatelet Activities of Green Synthesized Silver Nanoparticles Using Selaginella (Sanjeevini) Plant Extract","volume":"131","author":"Dakshayani","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_358","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1080\/10826068.2018.1479864","article-title":"Characterization, Antimicrobial, Antioxidant, and Anticoagulant Activities of Silver Nanoparticles Synthesized from Petiveria Alliacea L. Leaf Extract","volume":"48","author":"Lateef","year":"2018","journal-title":"Prep. Biochem. Biotechnol."},{"key":"ref_359","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1166\/jnn.2013.6906","article-title":"Green Synthesis and Nanotopography of Heparin-Reduced Gold Nanoparticles with Enhanced Anticoagulant Activity","volume":"13","author":"Kim","year":"2013","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_360","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/a-1384-3715","article-title":"Factor XI as a Target for New Anticoagulants","volume":"41","author":"Fredenburgh","year":"2021","journal-title":"Hamostaseologie"},{"key":"ref_361","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI Inhibition to Uncouple Thrombosis From Hemostasis: JACC Review Topic of the Week","volume":"78","author":"Hsu","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_362","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41573-020-0061-0","article-title":"Therapeutic Strategies for Thrombosis: New Targets and Approaches","volume":"19","author":"Mackman","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_363","doi-asserted-by":"crossref","first-page":"e13784","DOI":"10.1111\/cts.13784","article-title":"Pharmacokinetics, Pharmacodynamics, and Safety of Fesomersen, a Novel Antisense Inhibitor of Factor XI, in Healthy Chinese, Japanese, and Caucasian Volunteers","volume":"17","author":"Liu","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for Prevention of Venous Thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and Pharmacodynamics of Abelacimab (MAA868), a Novel Dual Inhibitor of Factor XI and Factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_366","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1056\/NEJMoa2406674","article-title":"Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation","volume":"392","author":"Ruff","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jjcc.2025.02.013","article-title":"Development of New Anticoagulants Targeting Coagulation Factor XI and Prospects for Clinical Use","volume":"85","author":"Ieko","year":"2025","journal-title":"J. Cardiol."},{"key":"ref_368","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/jth.15744","article-title":"First Randomized Evaluation of Safety, Pharmacodynamics, and Pharmacokinetics of BAY 1831865, an Antibody Targeting Coagulation Factor XI and Factor XIa, in Healthy Men","volume":"20","author":"Nowotny","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_369","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"ref_370","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/rth2.12186","article-title":"BAY 1213790, a Fully Human IgG1 Antibody Targeting Coagulation Factor XIa: First Evaluation of Safety, Pharmacodynamics, and Pharmacokinetics","volume":"3","author":"Thomas","year":"2019","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_371","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/ATVBAHA.118.312328","article-title":"Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial","volume":"39","author":"Lorentz","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_372","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1111\/bcp.15230","article-title":"Pharmacokinetics, Pharmacodynamics and Safety of BAY 2433334, a Novel Activated Factor XI Inhibitor, in Healthy Volunteers: A Randomized Phase 1 Multiple-Dose Study","volume":"88","author":"Kubitza","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_373","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/jth.15439","article-title":"First Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of BAY 2433334, a Small Molecule Targeting Coagulation Factor XIa","volume":"19","author":"Thomas","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_374","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1111\/bcp.14732","article-title":"ONO-7684 a Novel Oral FXIa Inhibitor: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in a First-in-Human Study","volume":"87","author":"Beale","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_375","doi-asserted-by":"crossref","unstructured":"Chen, R., Guan, X., Hu, P., Dong, Y., Zhu, Y., Zhang, T., Zou, J., and Zhang, S. (2022). First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.821363"},{"key":"ref_376","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","article-title":"Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy","volume":"65","author":"Dilger","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_377","doi-asserted-by":"crossref","unstructured":"Campello, E., Simioni, P., Prandoni, P., and Ferri, N. (2022). Clinical Pharmacology of Factor XI Inhibitors: New Therapeutic Approaches for Prevention of Venous and Arterial Thrombotic Disorders. J. Clin. Med., 11.","DOI":"10.3390\/jcm11216314"},{"key":"ref_378","doi-asserted-by":"crossref","first-page":"9500","DOI":"10.1021\/acsami.0c05750","article-title":"Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications","volume":"13","author":"Ni","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_379","doi-asserted-by":"crossref","first-page":"12079","DOI":"10.1021\/jacs.9b13370","article-title":"Aptamers as Versatile Molecular Tools for Antibody Production Monitoring and Quality Control","volume":"142","author":"Chen","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"ref_380","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00216-007-1643-y","article-title":"Aptamers as Molecular Recognition Elements for Electrical Nanobiosensors","volume":"390","author":"Lee","year":"2008","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_381","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.omtn.2019.03.002","article-title":"Rapidly Neutralizable and Highly Anticoagulant Thrombin-Binding DNA Aptamer Discovered by MACE SELEX","volume":"16","author":"Wakui","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_382","doi-asserted-by":"crossref","first-page":"12177","DOI":"10.1093\/nar\/gky990","article-title":"Several Structural Motifs Cooperate in Determining the Highly Effective Anti-Thrombin Activity of NU172 Aptamer","volume":"46","author":"Troisi","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_383","doi-asserted-by":"crossref","first-page":"9589","DOI":"10.1002\/chem.202001504","article-title":"Structure\u2013Activity Relationship Study of a Potent \u03b1-Thrombin Binding Aptamer Incorporating Hexitol Nucleotides","volume":"26","author":"Eremeeva","year":"2020","journal-title":"Chem. Eur. J."},{"key":"ref_384","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/978-3-030-34521-1_20","article-title":"Non-Anticoagulant Heparins as Heparanase Inhibitors","volume":"1221","author":"Cassinelli","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_385","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/glycob\/cwr053","article-title":"Bioactivity Screening of Partially Desulfated Low-Molecular-Weight Heparins: A Structure\/Activity Relationship Study","volume":"21","author":"Roy","year":"2011","journal-title":"Glycobiology"},{"key":"ref_386","doi-asserted-by":"crossref","first-page":"115312","DOI":"10.1016\/j.carbpol.2019.115312","article-title":"Identification of a Heparosan Heptasaccharide as an Effective Anti-Inflammatory Agent by Partial Desulfation of Low Molecular Weight Heparin","volume":"227","author":"Pan","year":"2020","journal-title":"Carbohydr. Polym."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/2\/163\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T15:54:55Z","timestamp":1769442895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/2\/163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":386,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["pharmaceutics18020163"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18020163","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]}}}